Bicara Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bicara Therapeutics Inc. - overview
Established
2020
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2020, Bicara Therapeutics Inc. is a clinical-stage firm that is developing biologics that combine targeted therapy with tumor modulators. As of March 2023, Claire Mazumdar serves as the CEO of the company. In December 2023, Bicara Therapeutics Inc.
raised USD 165 million in series C funding co-led by new investors TPG and Braidwell Lp, with participation from other investors Fairmount Partners, Aisling Capital, and Deerfield Management. Investors Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, and other investors also participated in the round. The company provides pipeline programs, including BCA101 and BCA356. BCA101 is a bifunctional antibody that is beneficial against a variety of tumor types, including head and neck tumors.
The firm's dual-action antibodies combine tumor-targeting antibodies' precision with tumor-microenvironment (TME) modulators' capability for a significant impact at the tumor's site. Bicara uses its platform to build bifunctional molecules to target the tumor and deliver the tumor-modulating payload while reducing side effects.
Current Investors
Eight Roads Ventures, Invus [DUP], F-Prime Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.bicara.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.